Difference between revisions of "Ixabepilone (Ixempra)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://packageinserts.bms.com/pi/pi_ixempra.pdf Ixabepilone (Ixempra) package insert]</ref><ref>[http://hemonc.org/do...") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://packageinserts.bms.com/pi/pi_ixempra.pdf Ixabepilone (Ixempra) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ixabepilone.pdf Ixabepilone (Ixempra) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.<ref name="insert">[http://packageinserts.bms.com/pi/pi_ixempra.pdf Ixabepilone (Ixempra) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/ixabepilone.pdf Ixabepilone (Ixempra) package insert (locally hosted backup)]</ref><ref>[http://www.ixempra.com/ Ixempra manufacturer's site]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://packageinserts.bms.com/pi/pi_ixempra.pdf#page=8 Ixabepilone (Ixempra) patient drug information]<ref>[http://packageinserts.bms.com/pi/pi_ixempra.pdf#page=8 Ixabepilone (Ixempra) patient drug information]</ref> | ||
*[http://chemocare.com/bio/ixabepilone.asp Ixabepilone (Ixempra) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ixabepilone.asp Ixabepilone (Ixempra) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/ixabepilone.asp Ixabepilone (Ixempra) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/ixabepilone.asp Ixabepilone (Ixempra) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ixabepilone-patient-drug-information Ixabepilone (Ixempra) patient drug information (UpToDate)]</ref> | ||
Revision as of 17:10, 22 February 2012
General information
Class/mechanism: Microtubule inhibitor; semi-synthetic analog of epothilone B. Ixabepilone binds to beta tubulin on microtubules, suppresses the dynamic instability of alpha beta II and alpha beta III, and disrupts normal microtubule dynamics. This results in arrest in the mitotic phase of the cell cycle and cell death.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Ixabepilone (Ixempra) patient drug information[4]
- Ixabepilone (Ixempra) patient drug information (Chemocare)[5]
- Ixabepilone (Ixempra) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 Ixabepilone (Ixempra) package insert
- ↑ Ixabepilone (Ixempra) package insert (locally hosted backup)
- ↑ Ixempra manufacturer's site
- ↑ Ixabepilone (Ixempra) patient drug information
- ↑ Ixabepilone (Ixempra) patient drug information (Chemocare)
- ↑ Ixabepilone (Ixempra) patient drug information (UpToDate)